



## EMMESSAR BIOTECH & NUTRITION LTD

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-49738167/68 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Site: [www.ebnl.org](http://www.ebnl.org)

Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

---

EBN/2019/S-2500

November 4, 2019

DCS - CRD  
The BSE Ltd  
Phiroze Jeebhoy Towers, 2<sup>nd</sup> floor  
Dalal Street, Fort, Mumbai – 400 001,

Dear Sir,

Sub: Filing of the advertisement copies of the Un-Audited Financial Results.

Ref: Company Code No. 524768

Pursuant to Regulation 47 of the SEBI [LODR] Regulations 2015, please find attached the copies of newspaper publication of Unaudited Financial Results for the quarter ended September 30, 2019, published in Free Press Journal and Nav Shakti on Saturday, November 2, 2019.

You are kindly requested to take the above on your records.

Thanking you,

Yours faithfully,  
For Emmessar Biotech & Nutrition Ltd

Compliance Officer  
Encl: As above





## Emmessar Biotech & Nutrition Ltd.

Registered Office: Plot No.T-3/2, MIDC, Talaja, Raigad Dist., Maharashtra - 410 208.  
CIN: L24110MH1992PLC06594229

### UNAUDITED FINANCIAL RESULTS FOR THE QUARTER / HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2019

(₹ In lakhs)

Sr. No.	Particulars	Unaudited					Audited
		Quarter Ended			Half Year Ended		Year Ended
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
I	Revenue from Operations	5.71	188.56	5.44	194.27	19.29	62.95
II	Other Income	35.78	35.37	31.53	71.15	62.55	129.99
	<b>Total Income (I + II)</b>	<b>41.49</b>	<b>223.93</b>	<b>36.97</b>	<b>265.42</b>	<b>81.84</b>	<b>192.94</b>
III	Expenses						
	Cost of material consumed	0.68	62.97	1.27	63.65	3.07	36.60
	Purchase of Stock-trade	0.39	12.45	0.00	12.84	4.50	17.95
	Change in Inventories of Finished goods	2.50	33.83	1.47	36.33	0.07	-42.14
	Employee Benefit Expenses	13.43	13.63	20.25	27.06	30.83	57.55
	Depreciation & Amortisation of Assets	1.45	1.45	2.15	2.90	4.30	7.86
	Other Expenditure	5.91	59.63	7.76	65.54	17.24	57.07
	<b>Total Expenses (IV)</b>	<b>24.36</b>	<b>183.96</b>	<b>32.90</b>	<b>208.32</b>	<b>60.01</b>	<b>134.89</b>
IV	Profit / (loss) from Operations before tax (III - IV)	17.13	39.97	4.07	57.10	21.83	58.05
V	Exceptional Items	0.00	0.00	0.00	0.00	0.00	28.67
VI	Profit / (loss) before tax	17.13	39.97	4.07	57.10	21.83	29.38
VII	Tax Expenses						
	1. Current Tax (MAT)	0.00	0.00	0.00	0.00	0.00	-6.00
	2. Deferred Tax	0.00	0.00	0.00	0.00	0.00	1.91
	3. MAT Credit	0.00	0.00	0.00	0.00	0.00	28.00
VIII	Net Profit / (loss) after tax (V - VI)	17.13	39.97	4.07	57.10	21.83	53.29
IX	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00	0.96
X	Total comprehensive income and Other Comprehensive Income	17.13	39.97	4.07	57.10	21.83	52.33
XI	Paid-up Equity Share Capital (Face Value of the share)	499.61	499.61	499.61	499.61	499.61	499.61
	Earning per Shares	10.00	10.00	10.00	10.00	10.00	10.00
	Basic	0.34	0.80	0.08	1.14	0.44	1.05
	Diluted	0.34	0.80	0.08	1.14	0.44	1.05

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 1st Nov 2019 and have been subject to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operates in three segments i.e. Healthcare, Fine Chemicals and Rent on leasehold land, during this quarter.
- Deferred tax & provision for taxation will be calculated annually.
- 1 Investor complaint was received and was disposed for the quarter ended 30th Sept 2019.

### Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30<sup>th</sup> Sept. 2019

(₹ In lakhs)

Sr. No.	Particulars	Unaudited					Audited
		Quarter Ended			Half Year Ended		Year Ended
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
1	<b>Segment Revenue</b>						
a	Healthcare	3.60	41.96	5.44	45.56	19.29	51.40
b	Fine Chemicals	2.11	146.60	0.00	148.71	0.00	11.55
c	Rent on leasehold land	33.78	33.78	30.71	67.56	61.42	125.92
d	Others	2.00	1.59	0.82	3.59	1.13	4.08
	<b>Total:</b>	<b>41.49</b>	<b>223.93</b>	<b>36.97</b>	<b>265.42</b>	<b>81.84</b>	<b>192.95</b>
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Net Sales / Income from Operations</b>	<b>41.49</b>	<b>223.93</b>	<b>36.97</b>	<b>265.42</b>	<b>81.84</b>	<b>192.95</b>
2	<b>Segment Results (Profit / Loss) before tax</b>						
a	Healthcare	2.00	26.72	2.36	28.72	10.83	29.21
b	Fine Chemicals	0.03	7.38	0.00	7.41	0.00	0.32
c	Rent on leasehold land	33.55	33.55	30.29	67.10	60.77	125.92
d	Others	2.00	1.59	0.82	3.59	1.13	4.08
	<b>Total:</b>	<b>37.58</b>	<b>69.24</b>	<b>33.47</b>	<b>106.82</b>	<b>72.73</b>	<b>159.53</b>
	Less:						
	Interest	0.00	0.00	0.00	0.00	0.00	0.00
	Other Unallocable Expenditure (net off)	20.45	29.27	29.40	49.72	50.90	101.48
	<b>Total Profit before Tax</b>	<b>17.13</b>	<b>39.97</b>	<b>4.07</b>	<b>57.10</b>	<b>21.83</b>	<b>58.05</b>
3	<b>Capital Employed (Segment Assets - Segment Liabilities)</b>						
a	Healthcare	7.30	7.87	11.32	7.30	11.32	7.97
b	Fine Chemicals	9.55	71.73	69.07	9.55	69.07	71.51
c	Rent on leasehold land	2.55	2.78	2.36	2.55	2.36	3.01
d	Others	192.49	172.84	237.56	192.49	237.56	179.41
	<b>Total:</b>	<b>211.89</b>	<b>255.22</b>	<b>320.31</b>	<b>211.89</b>	<b>320.31</b>	<b>261.90</b>

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature. The above results were taken on record at a meeting of the Board of Directors held on 1st November, 2019.

## Statements of Assets & Liabilities

(₹ In lakhs)

Particulars	As at 30.09.2019	As at 31.03.2019
<b>A ASSETS</b>		
<b>1 Non-current Assets</b>		
(a) Property, Plant & Equipment	131.92	134.30
(b) Investment Property	63.97	64.43
<b>Financial Assets</b>		
a) Loans	5.59	3.06
(b) Deferred Tax Assets (net)	48.02	76.03
(c) Other non-current assets	0.14	0.00
<b>Total non-current assets</b>	<b>249.64</b>	<b>277.82</b>
<b>2 Current Assets</b>		
(a) Current Investments	0.71	0.69
(b) Inventories	28.57	72.81
(c) Trade Receivables	3.57	3.83
(d) Cash & Cash equivalents	0.00	7.77
(e) Bank balance other than cash & Cash equivalents	184.41	63.67
(f) Loans	8.40	0.51
(g) Income tax assets (net)	41.76	12.89
(h) Other current assets	6.30	76.47
<b>Total current assets</b>	<b>273.73</b>	<b>238.64</b>
<b>TOTAL ASSETS</b>	<b>523.36</b>	<b>516.46</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>1 Equity Share Capital</b>		
(a) Share Capital	499.61	499.61
(b) Other Equity	(91.69)	(148.79)
<b>Total Equity</b>	<b>407.92</b>	<b>350.82</b>
<b>LIABILITIES</b>		
<b>2 Non-current Liabilities</b>		
(a) Other long term liabilities	61.42	61.42
(b) Long term provisions	17.05	14.29
<b>Total non-current liabilities</b>	<b>78.47</b>	<b>75.71</b>
<b>3 Current Liabilities</b>		
(a) Trade payables	15.31	7.17
(b) Other financial Liabilities	11.42	57.52
(c) Other current liabilities	1.30	18.42
(d) Short-term provisions	8.94	6.82
<b>Total current liabilities</b>	<b>36.97</b>	<b>89.93</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>523.36</b>	<b>516.46</b>

Mumbai  
1st Nov. 2019

By order of the Board  
**MSR Ayyangar**  
Managing Director